Register to receive a free U.S. Market Report Suite for Cardiac Rhythm Management Devices – MedSuite report synopsis and brochure

Abbott revealed the launch of their new and improved cardiac heart monitor, after being granted both CE Mark in Europe, as well as FDA clearance. This insertable device is extremely small, but exceptionally powerful; smartphone connectivity is combined with continuous remote monitoring to track irregular heart rhythm problems. In doing so, this will lead to efficient and accurate diagnosis of patients.

The Confirm Rx ICM device is inserted just under the skin and above the heart in the minimally invasive outpatient insertion procedure. This is the only ICM device on the market that has Bluetooth and smartphone synchronization, while also transmitting the collected data to the physician to quickly identify irregular heart rates. Abbott’s mobile app eradicates the need for an additional transmitter, while also being user-friendly, and offering translations in almost 40 languages.

“The rise in health monitoring has undoubtedly increased awareness of arrhythmias such as AFib, but many of these devices still aren’t leading to an improved diagnosis or solving the key clinical challenges for people at risk,” explains Sean Beinart, M.D., a cardiologist with Adventist Healthcare in Rockville, Md. “Like a guardian for heart health, Confirm Rx ICM can relay important data about a person’s heart rhythm through their smartphone and alert their care team to a potentially dangerous heart event. With Abbott’s new technology, I can better identify risk — making it actionable for me and life-changing for my patient.”

What makes Confirm Rx ICM so specialized is that unlike other monitoring technology that can lead to gaps in arrhythmia detection, Confirm Rx provides continuous monitoring 24/7. This advanced technology, SharpSense, reduces false detection by 97%.

The U.S. cardiac rhythm management market is being driven by the aging population and the increasing incidence of cardiovascular disease. Cardiovascular disease is much more prevalent among patients over 55 years of age; thus, as the U.S. population ages, the incidence of cardiovascular disease will increase. This market is also growing due to the improved ability to diagnose and treat cardiac arrhythmias. As the technology to diagnose arrhythmias such as microvolt T-wave alternans (MTWA), Holter and event monitors improves, the number of patients diagnosed with arrhythmias will continue to increase. Confirm Rx ICM is assisting this growth, as it has an extremely low false detection rate, but allows 24/7 monitoring for accurate and timely diagnosis.

Source